Hexarelin's cardiovascular record is real research, and almost all of it sits in laboratory animals and isolated tissue rather than in people. The compound is a synthetic hexapeptide in the growth hormone releasing peptide family, and its cardiac interest traces to two receptors: the classical secretagogue receptor GHS-R1a, and the scavenger receptor CD36, which is expressed in cardiac muscle and the vasculature and which hexarelin binds with notable affinity. Hexarelin holds no FDA approval for any indication and is sold in the United States as a Research Use Only compound, so everything below describes experimental and mechanistic work, not demonstrated human therapy.
Hexarelin's reported cardiovascular effects, including reduced infarct size, preserved left ventricular function, and limited cardiomyocyte apoptosis, are documented almost entirely in animal models and isolated tissue, with human evidence limited to small early-phase studies and no approved cardiovascular indication.
Two receptors carry hexarelin's cardiac pharmacology, not one, and the second is the reason the peptide acquired a cardiovascular literature at all. GHS-R1a is the familiar secretagogue receptor that mediates growth hormone release from the pituitary and is also present at lower levels in cardiac tissue; CD36 is a scavenger receptor on cardiomyocytes, vascular endothelium, and macrophages that binding studies identified as a specific cardiac binding site for hexarelin and related peptides. That distinction is what separates hexarelin from native ghrelin, which acts on cardiac tissue without binding CD36 the same way, and it is why cardiac effects that do not track GHS-R1a distribution have a mechanistic explanation at all.
| Criterion | GHS-R1a | CD36 |
|---|---|---|
| Where it sits | Pituitary, lower expression in cardiac tissue | Cardiomyocytes, vascular endothelium, macrophages |
| Role in growth hormone release | Mediates pituitary secretion | Not involved |
| Cardiac binding evidence | Receptor present; contribution to any given effect unsettled | Identified in radioligand studies as a specific cardiac binding site |
| Native ghrelin | Binds and acts on cardiac tissue | Not bound in the same way |
| Evidence level | Mechanistic and preclinical | Mechanistic and preclinical |
Radioligand and binding studies identified CD36, a scavenger receptor on cardiomyocytes and vascular endothelium, as a specific cardiac binding site for hexarelin distinct from the GHS-R1a pathway that drives growth hormone release, and the relative contribution of each receptor to any given cardiac effect remains unsettled.
Pump function is the most frequently reported cardiovascular observation in the hexarelin literature, and it is also the one most often read as more than it is. In this body of work, "improved left ventricular function" means a measured change in a rodent or an isolated heart preparation, not a treated patient.
Hexarelin improved left ventricular function in rodent models of cardiac injury and produced positive inotropic-like responses in isolated heart and papillary muscle preparations, findings that vary in magnitude by species, model, and dose and have no counterpart measure of clinical cardiac benefit in patients.
Cardioprotection is the reason hexarelin became a cardiovascular research subject instead of an endocrine footnote. Two families of models carry the evidence: acute ischemia and reperfusion, where blood flow to the heart is cut and then restored, and chronic injury models standing in for heart failure. Both report favorable results, and both are controlled animal experiments with defined injuries and short timelines, which is a different claim from protecting a human heart.
| Criterion | Ischemia and reperfusion models | Chronic injury and heart failure models |
|---|---|---|
| Reported effect | Reduced infarct size, blunted reperfusion injury | More favorable remodeling, less maladaptive structural change |
| Proposed mechanism | Survival signaling, reduced apoptosis under ischemic and oxidative stress | Same anti-apoptotic signaling across longer exposure |
| Growth hormone dependence | Effects preserved in animals unable to release growth hormone normally | Preserved in the same growth-hormone-deficient models |
| Evidence level | Animal models only; no human trials | Animal models only; no human trials |
In animal ischemia and reperfusion models hexarelin reduced infarct size and limited cardiomyocyte apoptosis, and those effects were preserved in animals rendered unable to release growth hormone normally, but no human trial has tested whether hexarelin protects the heart in cardiovascular disease.
How this question resolves decides how every other cardiovascular finding gets read: if the cardiac effects were only downstream of released growth hormone, hexarelin would be an endocrine story with a cardiac echo. The published record points strongly toward at least a partly independent, tissue-level action.
Hexarelin produced cardiac effects in hypophysectomized and growth-hormone-deficient animal models incapable of a normal growth hormone response, evidence of a direct tissue-level action layered alongside, rather than fully explained by, its growth hormone releasing property.
The human cardiovascular file on hexarelin is thin. Work in people has involved small numbers of subjects over short periods, built around the peptide's endocrine activity, with cardiovascular parameters recorded on the side rather than as the endpoint a trial was designed and powered to answer.
Hexarelin has no FDA approval as a cardiovascular therapy, and the human record consists of small, short, early-phase studies in which cardiovascular parameters were secondary observations, evidence properly described as preliminary and hypothesis-generating rather than sufficient for any clinical claim.
The vascular half of hexarelin's profile is the quieter one, and it often gets folded into cardioprotection claims as though it carried the same weight. It does not. CD36 and growth hormone secretagogue receptors are present on vascular smooth muscle and endothelium, and animal and isolated-vessel work has reported effects on vascular tone, but those endpoints were usually secondary measures inside studies asking other questions.
Hexarelin produced vasodilatory responses and modest effects on blood pressure and vascular resistance in animal and isolated-vessel studies acting through the same CD36 and secretagogue receptor systems as its cardiac effects, findings that were secondary endpoints and are less consistently reproduced than the cardiac work.
The most common error in reading this literature is treating animal cardioprotection as if it were demonstrated human therapy. A reduced infarct in a rodent model is a mechanistic clue about how the compound behaves in a controlled experiment, not a clinical result about what it does for a patient.
Hexarelin's cardiovascular evidence is animal and cell-based, its long-term cardiovascular safety in humans is essentially uncharacterized, and no randomized controlled trial has demonstrated improvement in survival, cardiac function, or event rates, leaving a genuinely interesting experimental profile that remains unproven as human treatment.
Educational use only. This article describes what the published scientific and clinical literature reports about Hexarelin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
